No Data
The new drug Efiglenatide developed by Yun Ding Xin Yao (01952) has been approved for上市 by the Hong Kong Department of Health for the treatment of moderate to severe active ulcerative colitis.
The Hong Kong Department of Health has officially approved the new drug application for etrasimod (VELSIPITY) for the treatment of moderate to severe active ulcerative colitis (UC) in adult patients.
Everest Medicines to Drop B Marker From Stock Short Name
EVEREST MED-B: 2024 Annual Report
Is There An Opportunity With Everest Medicines Limited's (HKG:1952) 49% Undervaluation?
EVEREST MED-B (01952): "Dual drivers + annual commercialization profitability" breaks the deadlock, aiming to set a new benchmark in Biopharma.
In recent years, amid the accelerated reform opportunities in the domestic Innovative Drugs market, EVEREST MED-B (01952) has fully accelerated innovation with a "dual-drive" approach, relying on strong independent research and development capabilities in Innovative Drugs and AI pharmaceuticals, supplemented by external authorization and partnership.
EVEREST MED-B (01952): Rules 18A.09 to 18A.11 do not apply.
EVEREST MED-B (01952) issued an announcement in accordance with the Hong Kong Exchange's Listing Rules Section 18...
Press Release: Everest Medicines Strengthens Management Team With Appointments of Chief Medical Officer and Chief Product Officer
